Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

被引:35
作者
Dell'Osso, Bernardo [1 ]
Mundo, Emanuela [1 ]
Marazziti, Donatella [2 ]
Altamura, A. Carlo [1 ]
机构
[1] Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Dept Psychiat, I-20122 Milan, Italy
[2] Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, I-56100 Pisa, Italy
关键词
obsessive compulsive disorder (OCD); treatment-resistance; serotonin and; norepinephrine reuptake inhibitors (SNRIs); Duloxetine;
D O I
10.1177/0269881107079865
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Obsessive compulsive disorder (OCD) is a chronic disorder, currently recognized as one of the most common psychiatric disorder as well as one of the most disabling of all medical disorders. OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments ( serotonin reuptake inhibitors and psychotherapy). Recent investigation showed that Venlafaxine, a dual serotonin and norepinephrine reuptake inhibitor (SNRI), may be a valid alternative for some treatment-refractory patients. We present the cases of four OCD patients with comorbid mood or anxiety disorders, who were treated with serotonin reuptake inhibitors (SRIs) at adequate doses for at least 12 weeks, showing partial/no response. Patients were then switched to Duloxetine up to 120 mg/day and followed up for 12 weeks. Three out of four patients showed a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score reduction >= 35%. Duloxetine may be helpful in patients with treatment-resistant OCD, although larger and controlled studies are warranted to confirm this preliminary observation.
引用
收藏
页码:210 / 213
页数:4
相关论文
共 19 条
  • [1] Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
    Bymaster, FP
    Dreshfield-Ahmad, LJ
    Threlkeld, PG
    Shaw, JL
    Thompson, L
    Nelson, DL
    Hemrick-Luecke, SK
    Wong, DT
    [J]. NEUROPSYCHOPHARMACOLOGY, 2001, 25 (06) : 871 - 880
  • [2] What is the optimal way to subdivide obsessive-compulsive disorder?
    de Mathis, Maria Alice
    Diniz, Juliana Belo
    do Rosario, Maria Conceicao
    Torres, Albina R.
    Hoexter, Marcelo
    Hasler, Gregor
    Miguel, Euripedes C.
    [J]. CNS SPECTRUMS, 2006, 11 (10) : 762 - +
  • [3] Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review
    Dell'Osso, Bernardo
    Nestadt, Gerald
    Allen, Andrea
    Hollander, Eric
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (04) : 600 - 610
  • [4] A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder
    Denys, D
    van der Wee, N
    van Megen, HJGM
    Westenberg, HGM
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) : 568 - 575
  • [5] Engleman EA, 1996, J NEUROCHEM, V66, P599
  • [6] First M. B., 2015, User's guide for the SCID-5-PD (Structured Clinical Interview for DSM-5 Personality Disorder)
  • [7] GOODMAN WK, 1990, ARCH GEN PSYCHIAT, V47, P577
  • [8] GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
  • [9] WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults
    Greist, JH
    Bandelow, B
    Hollander, E
    Marazziti, D
    Montgomery, SA
    Nutt, DJ
    Okasha, A
    Swinson, RP
    Zohar, J
    [J]. CNS SPECTRUMS, 2003, 8 (08) : 7 - 16
  • [10] A RATING SCALE FOR DEPRESSION
    HAMILTON, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1960, 23 (01) : 56 - 62